Skip to main content

Campbell Bradley L's Form 4 filing

Amicus Therapeutics, Inc.FOLD · filed Feb 21, 2025

Accession no.
0000950170-25-025118
Filed
Feb 21, 2025
Trade date
Feb 19, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $4.00K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Campbell Bradley LCIK 0001400971Director, Officer (President and CEO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 19, 2025Common StockMOption exerciseAcquired+400$9.03+$3,6121,151,057Direct
Feb 19, 2025Common StockSSaleDisposed−400$10.00−$4,0001,150,657Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 19, 2025Common StockMOption exerciseDisposed−400$0.00$099,600Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Remarks

All transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2024.

Read the full filing on SEC EDGAR (opens in a new tab)